GlassScriptPhysician profile
Adrienne K Earl
NPI 1790190817
$6,786.51
in general payments reported to CMS, 2019-2025
32 companies · $53.68 in 2025
The $53.68 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,215 · 2022: $1,626 · 2023: $1,969 · 2024: $1,923 · 2025: $53.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Education: $15.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.96 |
| Education | $15.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,151.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,052.13 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $529.64 | 2021-2024 | Stelara, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $330.36 | 2021-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $236.48 | 2024 | Voquezna |
| Pfizer INC. | $222.78 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $221.20 | 2021-2024 | Linzess |
| Genzyme Corporation | $202.49 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.79 | 2021-2024 | Entyvio, Gattex |
| Evoke Pharma, INC. | $149.93 | 2021-2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $136.43 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $136.27 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $129.86 | 2021-2023 | |
| Ardelyx, INC. | $127.04 | 2022-2024 | Ibsrela |
| Janssen Scientific Affairs, LLC | $123.03 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $115.07 | 2021-2023 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $112.87 | 2022 | |
| Ferring Pharmaceuticals INC. | $111.59 | 2021-2024 | Clenpiq, Rebyota |
| Qol Medical, LLC | $69.02 | 2023-2024 | Sucraid, Sucraid |
| Celgene Corporation | $54.00 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $51.74 | 2021-2022 | |
| Lilly USA, LLC | $49.99 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $48.94 | 2024 | Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.98 | 2025 | |
| Fresenius Kabi USA, LLC | $32.35 | 2023 | Idacio |
| Organon LLC | $30.31 | 2024 | |
| Alexion Pharmaceuticals, INC. | $30.26 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $25.47 | 2024 | Iqirvo |
| Vivus LLC | $23.36 | 2021 | |
| Redhill Biopharma INC. | $22.68 | 2021 | |
| Aimmune Therapeutics, INC. | $16.03 | 2024 | |
| Exact Sciences Corporation | $13.88 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.